GSK Forges Comeback in China with Blood Cancer Drug Push

GlaxoSmithKline is making a significant return to the Chinese market, aiming to re-establish its presence after a challenging period that included a substantial bribery fine in 2014. The company is now focusing on expanding its oncology portfolio through collaborations and acquisitions within China's pharmaceutical industry.

Twelve years ago, GlaxoSmithKline faced severe repercussions when a Chinese court fined the company £300 million and found it guilty of operating a widespread bribery network. The investigation revealed that the pharmaceutical giant had bribed healthcare officials with gifts, including sexual favors, to promote the prescription of GSK's drugs. The former head of Chinese operations, Mark Reilly, received a suspended prison sentence and was deported.

Strategic Pivot to Oncology

Under the leadership of CEO Luke Miels, who took the helm in January, GSK is now prioritizing cancer medicines. Miels believes that forging partnerships with Chinese firms focused on drug discovery is key to addressing the company's current limitations in its oncology pipeline. This strategy represents a significant shift and a renewed focus on growth prospects in cancer treatment.

In a recent move, GSK signed a £550 million deal to acquire an early-stage oncology drug from Chimagen Biosciences. This drug utilizes T-cells, which are designed to engage the immune system to combat cancer. GSK is hopeful about its potential effectiveness in treating multiple myeloma, a type of blood cancer, with initial trials planned for next year.

This acquisition follows a previous licensing agreement with Hansoh Pharmaceutical, another Chinese company. Miels described this partnership as potentially transformational, noting that GSK opted for collaboration rather than outright acquisition of Chinese firms, a path taken by some competitors like Merck. Miels, a former scientist at AstraZeneca, recognized Hansoh's expertise and proposed a partnership where GSK would handle global development while Hansoh retained rights within China.

This collaboration has yielded promising results. Hansoh's drug, Ris-Rez, has demonstrated a 54% reduction in the risk of death compared to competing products for small cell lung cancer in China. GSK is now developing and testing Ris-Rez for small cell lung cancer and other solid tumors outside of China. The drug uses antibody-drug conjugates (ADCs) to target cancer cells. Hesham Abdullah, GSK’s head of oncology research and development, considers Ris-Rez an 'important step forward' in the company's lung cancer strategy, with potential applications in treating prostate and ovarian cancers as well.

Lessons from Competitors and Past Experiences

GSK's renewed engagement in China mirrors the successful expansion strategies of rival AstraZeneca, which has established China as its second-largest market after the US, largely through its work on immunology treatments. Miels is keen to establish GSK as a leader in oncology, particularly as the company faces upcoming patent expirations on its HIV drugs. Efforts are also underway to develop a simpler, oral version of these HIV treatments.

Reflecting on the company's past, Miels expressed optimism about developing a gastric cancer treatment based on a company acquired in California. The current strategy signifies a remarkable comeback for GSK in China, a market it had significantly alienated over a decade ago. Despite the past scandal, GSK's commitment to China, first articulated by former CEO Sir Andrew Witty, appears to be realized through Walmsley's cleanup efforts and Miels's ambitious expansion plans. Investor confidence in GSK has also grown, with its shares increasing by 27% over the past year.